Curative-intent tri-modality treatment of de novo bone-only oligometastatic breast cancer: single-center patient outcomes
{{output}}
Introduction: It is estimated that 10-25% of breast cancer patients have metastatic disease upon diagnosis with roughly 20% having limited metastatic sites. The optimal management of patients with de novo bone-only oligometastati... ...
